Why Is Praxis (PRAX) Stock So Bullish Today?

As of the most recent check, Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock was up 25.91% to trade at $39.60 on the charts, showing signs of strength. Praxis’s stock has increased following the publishing of a business update.

Praxis (PRAX) has given an update on its portfolio and anticipated major events for 2024. Phase 2a PPR study topline data for PRAX-628 are anticipated in the first quarter of 2024, and the Phase 2b trial on focal epilepsy is anticipated to begin in the same year.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

The second half of 2024 will see the topline findings of both Phase 3 trials assessing ulixacaltamide in essential tremor. Finalize regulatory relationships to move elsunersen (PRAX-222) in the direction of a crucial investigation for the management of developmental epilepsies caused by SCN2A gain-of-function (GOF).

Results from the first half of 2024’s Phase 2 EMBOLD investigation of PRAX-562 in developing epilepsies of SCN2A and SCN8A. Praxis is beginning 2023 with four products in the clinic: ulixacaltamide, the main program, and PRAX-628, which keeps demonstrating its promise as a best-in-class epileptic medication.

Praxis is building on the progress of an exciting 2023. PRAX’s dedication to achieving the worldwide benefit of its initiatives is demonstrated by the newly disclosed collaboration with Tenacia, which expands the availability of ulixacaltamide to Greater China.

Over a million Americans suffer from focal epilepsy; Praxis made significant advancements in developing PRAX-628 to treat this condition. PRAX-628 has an excellent tolerability characteristic, a potentially broad therapeutic index, and it can achieve effective concentrations in less than a day, according to preliminary research.

Praxis is carrying up a Phase 2a PPR trial to assess PRAX-628’s effectiveness in two cohorts at doses of 15 mg and 45 mg. PPR studies, which assess EEG signatures following sporadic photic stimulation, are frequently employed to help determine dosage and serve as a gauge of anti-seizure effectiveness. Numerous innovative and licensed medicines have validated this strategy.

Most Popular